A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
Latest Information Update: 29 Jul 2024
At a glance
- Drugs BCMA GPRC5D CAR-T cell therapy Guangzhou Bio-gene Technology (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 29 Jul 2024 New trial record